Advertisement

Latest News

HFmrEF as a Unique Phenotype of Heart Failure, With Jane Wilcox, MD, MSc

1 hour ago

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD

4 hours ago

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial

4 hours ago

Retatrutide successfully reduced body weight versus placebo in adults with obesity or overweight in topline phase 3 TRIUMPH-1 results.

Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD

5 hours ago

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease

6 hours ago

New ATP7B gene therapies aim to normalize copper in Wilson’s disease, reducing chelation needs while raising durability and patient-selection questions.

Advertisement
Advertisement